178 related articles for article (PubMed ID: 29950528)
1. CD30, CD15, CD50, and PAX5 Expressions as Diagnostic Markers for Hodgkin Lymphoma (HL) and Systemic Anaplastic Large Cell Lymphoma (sALCL).
Ranuhardy D; Suzanna E; Sari RM; Hadisantoso DW; Andalucia R; Abdillah A
Acta Med Indones; 2018 Apr; 50(2):104-109. PubMed ID: 29950528
[TBL] [Abstract][Full Text] [Related]
2. CD15, CD30, and PAX5 evaluation in Hodgkin's lymphoma on fine-needle aspiration cytology samples.
Cozzolino I; Vitagliano G; Caputo A; Montella M; Franco R; Ciancia G; Selleri C; Zeppa P
Diagn Cytopathol; 2020 Mar; 48(3):211-216. PubMed ID: 31825183
[TBL] [Abstract][Full Text] [Related]
3. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
[TBL] [Abstract][Full Text] [Related]
4. The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas.
Macalalad AR; McAuliffe M; Yang H; Kageleiry A; Zhong Y; Wu EQ; Shonukan O; Bonthapally V
Curr Med Res Opin; 2015 Mar; 31(3):537-45. PubMed ID: 25598441
[TBL] [Abstract][Full Text] [Related]
5. Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients.
Gharbaran R; Goy A; Tanaka T; Park J; Kim C; Hasan N; Vemulapalli S; Sarojini S; Tuluc M; Nalley K; Bhattacharyya P; Pecora A; Suh KS
J Hematol Oncol; 2013 Aug; 6():62. PubMed ID: 23988031
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients.
Gandolfi L; Pellegrini C; Casadei B; Stefoni V; Broccoli A; Tonialini L; Morigi A; Argnani L; Zinzani PL
Oncologist; 2016 Dec; 21(12):1436-1441. PubMed ID: 27486201
[TBL] [Abstract][Full Text] [Related]
7. Hodgkin lymphoma with unusual intrasinusoidal pattern of infiltration.
Lee SS; Ryoo BY; Park YH; Park S; Kim MS; Park KH; Kim CW
Leuk Lymphoma; 2004 Oct; 45(10):2135-41. PubMed ID: 15370261
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemistry of Hodgkin and non-Hodgkin lymphomas with emphasis on the diagnostic significance of the BNH9 antibody reactivity with anaplastic large cell (CD30 positive) lymphomas.
Carbone A; Gloghini A; Volpe R
Cancer; 1992 Dec; 70(11):2691-8. PubMed ID: 1330287
[TBL] [Abstract][Full Text] [Related]
9. IRF8 as a Novel Marker to Differentiate Between CD30-Positive Large Cell Lymphomas.
McQuaid DC; Katz SG; Xu ML
Am J Clin Pathol; 2022 Aug; 158(2):173-176. PubMed ID: 35460405
[TBL] [Abstract][Full Text] [Related]
10. Nodal involvement by cutaneous CD30-positive T-cell lymphoma mimicking classical Hodgkin lymphoma.
Eberle FC; Song JY; Xi L; Raffeld M; Harris NL; Wilson WH; Pittaluga S; Jaffe ES
Am J Surg Pathol; 2012 May; 36(5):716-25. PubMed ID: 22367293
[TBL] [Abstract][Full Text] [Related]
11. Use of an expanded immunohistochemical panel to distinguish cutaneous Hodgkin lymphoma from histopathologic imitators.
Cho RJ; McCalmont TH; Ai WZ; Fox LP; Treseler P; Pincus LB
J Cutan Pathol; 2012 Jun; 39(6):651-8. PubMed ID: 22324490
[TBL] [Abstract][Full Text] [Related]
12. CD30-positive T-cell lymphomas co-expressing CD15: an immunohistochemical analysis.
Gorczyca W; Tsang P; Liu Z; Wu CD; Dong HY; Goldstein M; Cohen P; Gangi M; Weisberger J
Int J Oncol; 2003 Feb; 22(2):319-24. PubMed ID: 12527929
[TBL] [Abstract][Full Text] [Related]
13. IMP3 as a supplemental diagnostic marker for Hodgkin lymphoma.
Tang H; Wei Q; Ge J; Jian W; Liu J; Zhong L; Fu B; Zhao T
Hum Pathol; 2013 Oct; 44(10):2167-72. PubMed ID: 23845468
[TBL] [Abstract][Full Text] [Related]
14. A sinusoidal large cell lymphoma with expression of CD30, CD15, and multiple B-cell antigens: a classical Hodgkin lymphoma with sinusoidal infiltrating pattern or a sinusoidal CD30 positive large B-cell lymphoma with CD15?
Wang E; Foo WC; Huang Q
Leuk Lymphoma; 2010 Jun; 51(6):1148-51. PubMed ID: 20443679
[No Abstract] [Full Text] [Related]
15. Peripheral T-cell lymphomas expressing CD30 and CD15.
Barry TS; Jaffe ES; Sorbara L; Raffeld M; Pittaluga S
Am J Surg Pathol; 2003 Dec; 27(12):1513-22. PubMed ID: 14657710
[TBL] [Abstract][Full Text] [Related]
16. Classical Hodgkin lymphoma type post-transplant lymphoproliferative disorder in a kidney transplant recipient: a diagnostic pitfall.
Mohri T; Ikura Y; Hirakoso A; Okamoto M; Hishizawa M; Takaori-Kondo A; Kato S; Nakamura S; Yoshimura K; Okabe H; Iwai Y
Int J Hematol; 2018 Aug; 108(2):218-227. PubMed ID: 29380181
[TBL] [Abstract][Full Text] [Related]
17. PAX-5 Positivity in Anaplastic Lymphoma Kinase-Negative Anaplastic Large Cell Lymphoma: A Case Report and Review of Literature.
Arun I; Roy P; Arora N; Bhave SJ; Nair R; Chandy M
Int J Surg Pathol; 2017 Jun; 25(4):333-338. PubMed ID: 28013563
[TBL] [Abstract][Full Text] [Related]
18. Cytomorphologic differentiation of Hodgkin's lymphoma and Ki-1+ anaplastic large cell lymphoma in fine needle aspirates.
Mourad WA; al Nazer M; Tulbah A
Acta Cytol; 2003; 47(5):744-8. PubMed ID: 14526672
[TBL] [Abstract][Full Text] [Related]
19. JAK2 Rearrangements Are a Recurrent Alteration in CD30+ Systemic T-Cell Lymphomas With Anaplastic Morphology.
Fitzpatrick MJ; Massoth LR; Marcus C; Vergilio JA; Severson E; Duncan D; Ramkissoon SH; Hasserjian RP; Kim AS; Sohani AR; Williams EA; Nardi V
Am J Surg Pathol; 2021 Jul; 45(7):895-904. PubMed ID: 34105517
[TBL] [Abstract][Full Text] [Related]
20. [Expression and significance of B-cell-specific activator protein of H/RS cell in classical Hodgkin's Lymphoma].
Zhou X; Zhao T; Qi Z; Liu G; Zhu M
Zhonghua Yi Xue Za Zhi; 2002 Nov; 82(22):1532-5. PubMed ID: 12609061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
